Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Central serous chorioretinopathy: An evidence-based treatment guideline
Helena M.A. Feenstra
, Elon H.C. van Dijk
, Chui Ming Gemmy Cheung
, Kyoko Ohno-Matsui
, Timothy Y.Y. Lai
, Hideki Koizumi
, Michael Larsen
, Giuseppe Querques
, Susan M. Downes
, Suzanne Yzer
, Mark P. Breazzano
, Yousif Subhi
, Ramin Tadayoni
, Siegfried G. Priglinger
, Laurenz J.B. Pauleikhoff
, Clemens A.K. Lange
,
Anat Loewenstein
, Roselie M.H. Diederen
, Reinier O. Schlingemann
, Carel B. Hoyng
Jay K. Chhablani, Frank G. Holz, Sobha Sivaprasad, Andrew J. Lotery, Lawrence A. Yannuzzi, K. Bailey Freund, Camiel J.F. Boon
*
Show 7 others
Show less
*
Corresponding author for this work
Ophthalmology
Leiden University
Singapore National Eye Center
Duke-NUS Graduate Medical School
Institute of Science Tokyo
Chinese University of Hong Kong
University of the Ryukyus
University of Copenhagen
Vita-Salute San Raffaele University
Oxford University Hospitals NHS Foundation Trust
University of Oxford
Radboud University Nijmegen
Retina-Vitreous Surgeons of Central New York
SUNY Upstate Medical University
University of Southern Denmark
Université Paris Cité
Ludwig Maximilian University of Munich
Academic Medical Centre
University of Freiburg
St. Franziskus-Hospital Münster
University of Lausanne
University of Pittsburgh
University of Bonn
Moorfields Eye Hospital NHS Foundation Trust
University of Southampton
Vitreous Retina Macula Consultants of New York
Manhattan Eye, Ear and Throat Hospital
New York University
Research output
:
Contribution to journal
›
Review article
›
peer-review
71
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Central serous chorioretinopathy: An evidence-based treatment guideline'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Clinical Practice Guidelines
100%
Evidence-based Treatment
100%
Central Serous Chorioretinopathy
100%
Half-dose
27%
Half-dose Photodynamic Therapy
27%
Subretinal Fluid
18%
Verteporfin
18%
Therapeutic Strategies
9%
Early Treatment
9%
Common Disease
9%
Randomized Controlled Trial
9%
Paucity
9%
Treatment Options
9%
Non-central
9%
Current Therapeutics
9%
Angiography
9%
Fluid Leakage
9%
Epithelial Layer
9%
Vision Loss
9%
Macular
9%
Photodynamic Therapy
9%
New Treatment Options
9%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
9%
Intravitreal Injection
9%
Treatment Algorithm
9%
Vision-related Quality of Life
9%
Blood-retinal Barrier
9%
Reduced Vision
9%
Retinal pigment Epithelial
9%
Photosensitive Dye
9%
Macular Neovascularization
9%
Conventional Laser Photocoagulation
9%
Choroidal Abnormality
9%
Medicine and Dentistry
Central Serous Retinopathy
100%
Photochemotherapy
36%
Subretinal Fluid
18%
Verteporfin
18%
Quality of Life
9%
Randomized Controlled Trial
9%
Vasculotropin
9%
Angiography
9%
Low Vision
9%
Visual Impairment
9%
Retinal Pigment Epithelium
9%
Choroid
9%
Intravitreal Administration
9%
Laser Coagulation
9%
Blood-Retinal Barrier
9%
Diseases
9%
Pharmacology, Toxicology and Pharmaceutical Science
Central Serous Retinopathy
100%
Photodynamic Therapy
36%
Verteporfin
18%
Subretinal Fluid
18%
Randomized Controlled Trial
9%
Vasculotropin
9%
Visual Impairment
9%
Neovascularization (Pathology)
9%
Intravitreal Administration
9%
Visual Pigment
9%
Low Vision
9%
Diseases
9%
Immunology and Microbiology
Photodynamics
100%
Vasculotropin
25%
Neovascularization (Pathology)
25%
Retinal Pigment Epithelium
25%
Choroid
25%
Blood Retina Barrier
25%
Neuroscience
Central Serous Chorioretinopathy
100%
Verteporfin
18%
Randomized Controlled Trial
9%
Vascular Endothelial Growth Factor
9%
Choroid
9%
Visual Pigment
9%
Blood Retina Barrier
9%
Angiography
9%